SCYNEXIS, Inc. (NASDAQ:SCYX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 9, 2018, the Board of Directors of SCYNEXIS, Inc. took the following compensation actions with respect to SCYNEXIS’s executive officers (collectively, the “Officers”):
2017 Officer Bonuses
Approved cash bonuses for the Officers based on SCYNEXIS’s performance for the calendar year 2017, as follows:
|
Executive Officer |
Title |
Bonus |
|
Marco Taglietti, M.D. |
Chief Executive Officer |
$140,300 |
|
David Angulo, M.D. |
Chief Medical Officer |
$124,200 |
|
Eric Francois |
Chief Financial Officer |
$97,400 |
|
Scott Sukenick |
General Counsel |
$16,000 |
2018 Salaries
Approved the 2018 annual base salaries for the Officers, to be effective March 1, 2018, as follows:
|
Executive Officer |
Title |
2018 Salary |
|
Marco Taglietti, M.D. |
Chief Executive Officer |
$530,000 |
|
David Angulo, M.D. |
Chief Medical Officer |
$426,300 |
|
Eric Francois |
Chief Financial Officer |
$371,400 |
|
Scott Sukenick |
General Counsel |
$320,000 |
Option Grants
Approved stock option grants under SCYNEXIS 's 2014 Equity Incentive Plan to the Officers, as follows:
|
Executive Officer |
Title |
Shares subject to Option |
|
Marco Taglietti, M.D. |
Chief Executive Officer |
375,000 |
|
David Angulo, M.D. |
Chief Medical Officer |
200,000 |
|
Eric Francois |
Chief Financial Officer |
150,000 |
|
Scott Sukenick |
General Counsel |
15,000 |
The options have an exercise price of $1.69 per share and vest on a monthly basis over a four-year period, provided such Officer is continuing to provide services to SCYNEXIS on such vesting date.
About SCYNEXIS, Inc. (NASDAQ:SCYX)
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.